XML 44 R28.htm IDEA: XBRL DOCUMENT
v3.22.4

Available for Sale Debt Securities (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract] |
Summary of Available for Sale Debt Securities | The table below summarizes our available for sale debt securities recorded at fair value as of December 31, 2022 and 2021 (in thousands):
| Cost |  | Unrealized (Losses)/Gains |  | Fair Value |  |  | Current Assets |  | Non-Current Assets |  | Current Liabilities |  | Non-Current Liabilities |  | Total
As of December 31, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Debt securities (1) | $ | 359,400 |  |  | $ | (131,800) |  |  | $ | 227,600 |  |  |  | $ | 1,300 |  |  | $ | 226,300 |  |  | $ | — |  |  | $ | — |  |  | $ | 227,600 |
Funding commitments (2) | (9,400) |  |  | 6,900 |  |  | (2,500) |  |  |  | — |  |  |  |  | — |  |  | (2,500) |  |  | (2,500) |
Total available for sale debt securities | $ | 350,000 |  |  | $ | (124,900) |  |  | $ | 225,100 |  |  |  | $ | 1,300 |  |  | $ | 226,300 |  |  | $ | — |  |  | $ | (2,500) |  |  | $ | 225,100 |
As of December 31, 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Debt securities (3) | $ | 204,509 |  |  | $ | 49,191 |  |  | $ | 253,700 |  |  |  | $ | 66,000 |  |  | $ | 187,700 |  |  | $ | — |  |  | $ | — |  |  | $ | 253,700 |
Forwards (4) | — |  |  | 16,700 |  |  | 16,700 |  |  |  | — |  |  | 16,700 |  |  | — |  |  | — |  |  | 16,700 |
Total available for sale debt securities | $ | 204,509 |  |  | $ | 65,891 |  |  | $ | 270,400 |  |  |  | $ | 66,000 |  |  | $ | 204,400 |  |  | $ | — |  |  | $ | — |  |  | $ | 270,400 |
(1)The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. The cost of the Development Funding Bonds represents the amounts funded. (2)The cost associated with the Cytokinetics Funding Commitments represents the fair value on the purchase date. (3)The cost for the Series A Biohaven Preferred Shares represents amortized cost. The cost for the Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. These instruments were fully redeemed during 2022. (4)There are no costs associated with the forwards.

X
- Definition Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -URI https://asc.fasb.org/topic&trid=2196928 + Details
Name: | us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration